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INTRODUCTION
Fabry disease (MIM 301500) is a rare and progressive X-linked 
disorder that is due to deficiency of lysosomal α-galactosidase 
A (α-Gal A; MIM 300644, EC3.2.1.22).1 The accumulation of 
glycosphingolipid substrates leads to impairment of kidney, 
heart, and brain function and to early death.2
To date, more than 800 Fabry disease–associated mutations 
to the gene encoding α-Gal A (GLA) have been identified. 
Approximately 60% are missense mutations resulting in single 
amino acid substitutions in α-Gal A.2,3 Missense mutations 
result in heterogeneous phenotypes ranging from classic to 
nonclassic.4–7
Oral migalastat (1-deoxygalactonojirimycin, AT1001), a low-
molecular-weight pharmacological chaperone, is being devel-
oped for Fabry disease as an alternative to intravenous enzyme 
replacement therapy (ERT). Migalastat binds to the active site 
of specific mutant forms of α-Gal A, thus stabilizing the enzyme 
and restoring trafficking to lysosomes where the enzyme can 
catabolize substrates.8–11
Certain patients with Fabry disease produce mutant forms of 
α-Gal A that are amenable to migalastat. These patients express 
mutant forms of α-Gal A that show increased total cellular α-Gal 
A activity after treatment with migalastat. These mutant forms 
are commonly single missense mutations in GLA,10–13 although 
some may be small in-frame insertions, deletions, or multiple-site 
missense mutations. Mutations in GLA that impair the synthesis 
of α-Gal A or severely affect protein structure (e.g., frameshift, 
truncation, large insertion or deletion mutations) and catalytic 
activity are expected to lead to mutant forms of α-Gal A that do 
not show increased cellular activity in response to migalastat.
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Purpose: Fabry disease is an X-linked lysosomal storage  disorder 
caused by mutations in the α-galactosidase A gene. Migalastat, 
a pharmacological chaperone, binds to specific mutant forms of 
α-galactosidase A to restore lysosomal activity.
Methods: A pharmacogenetic assay was used to identify the 
α-galactosidase A mutant forms amenable to migalastat. Six hundred 
Fabry disease–causing mutations were expressed in HEK-293 (HEK) 
cells; increases in α-galactosidase A activity were measured by a good 
laboratory practice (GLP)-validated assay (GLP HEK/Migalastat 
Amenability Assay). The predictive value of the assay was assessed 
based on pharmacodynamic responses to migalastat in phase II and 
III clinical studies.
Results: Comparison of the GLP HEK assay results in in vivo white 
blood cell α-galactosidase A responses to migalastat in male patients 
showed high sensitivity, specificity, and positive and negative predic-
tive values (≥0.875). GLP HEK assay results were also predictive of 
decreases in kidney globotriaosylceramide in males and plasma glo-
botriaosylsphingosine in males and females. The clinical study subset 
of amenable mutations (n = 51) was representative of all 268 ame-
nable mutations identified by the GLP HEK assay.
Conclusion: The GLP HEK assay is a clinically validated method of 
identifying male and female Fabry patients for treatment with mig-
alastat.
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Cell-based studies have shown that migalastat increases the 
levels of many different mutant forms of α-Gal A.11,14–17 The 
migalastat-mediated increases were consistent across different 
cell lines with the same mutation.11 The cell-based responses of 
19 α-Gal A mutant forms to a clinically achievable concentra-
tion of migalastat (10 µmol/l) were generally consistent with 
observed increases in α-Gal A activity in peripheral blood 
mononuclear cells (PBMCs) from male Fabry patients who 
were orally administered migalastat.16
Prior to the current study, only a small percentage of the 
approximately 800 GLA mutations that cause Fabry disease 
had been evaluated for their response to migalastat. These stud-
ies9,11,12,14–17 used different research-based assays with varying 
procedures, quality controls, and acceptance criteria. Many 
were conducted using patient-derived cells, fluids, or tissues. 
Samples derived from female patients present a challenge 
because the cells are a mixture that expresses either wild-type 
or mutant forms of α-Gal A.18 The measured α-Gal A activ-
ity in these cells is dominated by the wild-type enzyme, which 
is responsive to migalastat complicating the interpretation. 
Hence, neither the baseline activity nor the effect of migalastat 
on the mutant form can be accurately determined from cells 
from female Fabry patients.
In the current study, a good laboratory practice (GLP)-
validated in vitro assay was used to express each of 600 pri-
marily missense Fabry disease–causing mutations for testing 
in human embryonic kidney 293 (HEK) cells and measur-
ing increases in α-Gal A activity in response to migalastat. 
An amenable mutant form of α-Gal A in the GLP HEK (i.e., 
migalastat amenability) assay was defined by α-Gal A activ-
ity in the presence of 10 µmol/l migalastat that is ≥1.20-fold 
over baseline with an absolute increase of ≥3.0% wild-type 
α-Gal A activity. Clinical validation of the assay was assessed 
based on Fabry disease patient pharmacodynamic responses 
in phase II and III clinical studies. Seventy-three unique 
amenable and nonamenable mutations were represented in 
these studies.
MATERIALS AND METHODS
Mutations that qualify for testing in the GLP-validated 
human embryonic kidney 293 cell in vitro assay
Fabry disease–causing GLA mutations that qualify for testing 
include missense mutations, nonsense mutations near the car-
boxyl terminus, small insertions and deletions that maintain 
reading frame, and complex mutations comprising two or more 
of these types of mutations on a single GLA allele.
Mutations that do not qualify for testing include large dele-
tions, insertions, truncations, frameshift mutations, and splice-
site mutations. These types of mutations grossly alter the 
structure and function of the enzyme and may result in com-
plete loss of expression.
Mutations that do not qualify for testing in the GLP HEK 
assay are categorized as nonamenable (see the criteria for ame-
nable mutation below).
Summary of the GLP HEK assay method
Qualifying Fabry disease–associated mutations were identi-
fied from the Human Gene Mutation Database (http://www.
hgmd.cf.ac.uk/ac), the Shire Human Genetic Therapies Fabry 
Outcome Survey registry (https://www.fabryos.com; accessed 
on or before 30 June 2009), clinical studies with migalastat, 
and other public sources. Qualified mutations (total number: 
600) were engineered into a mammalian expression vector 
(pcDNA6/v5-His A) containing the human α-Gal A cDNA 
(Supplementary Figure S1 online) as previously described.16
The resultant recombinant mutant, wild-type (WT), or vector 
pcDNA constructs underwent validated DNA quality- control 
assessments conducted in compliance with relevant GLP regu-
lations. Plasmids meeting the prespecified DNA quality-accep-
tance criteria were used for transfection.
HEK-293 cells were seeded into 96-well plates, transfected 
with individual mutant GLA-containing DNA plasmids, and 
incubated in the presence or absence of 10 µmol/l migalastat for 
5 days. Then, lysis buffer was added to obtain cell lysates, which 
were assayed for total protein and α-Gal A activity. Transfection 
efficiency was measured as the amount of GLA cDNA in the cell 
lysates detected by qPCR.
The α-Gal A activity in each cell lysate was measured 
using the fluorogenic substrate, 4-methylumbelliferyl-α- 
d-galactopyranoside, and normalized to the total protein. 
The endogenous α-Gal A activity, as measured in empty 
vector-transfected cell lysates, was subtracted from the activ-
ity in mutant or wild type–transfected cell lysates. The resul-
tant activity for each α-Gal A mutant form, in the presence 
or absence of 10 µmol/l migalastat, was thereby obtained and 
used to determine its response to 10 µmol/l migalastat. See the 
Supplementary Material online for the detailed methodology.
Amenable mutation criteria
Mutant forms that qualified for testing in the GLP HEK assay 
and showed α-Gal A activity in the presence of 10 µmol/l mig-
alastat that is ≥1.20-fold over baseline with an absolute increase 
of ≥3.0% wild-type α-Gal A activity (equations provided in 
Supplementary Material online) and their corresponding GLA 
mutations were categorized as amenable. The approximate aver-
age maximum concentration measured in the plasma of Fabry 
patients following a single oral administration of 150 mg mig-
alastat HCl is 10 µmol/l.19 The 3.0% wild-type minimum abso-
lute increase was based on literature indicating that increases 
of 1 to 5% of normal enzyme activity in vivo may be clinically 
meaningful.20,21 The 1.20-fold over baseline criterion was speci-
fied to require mutant forms with high baseline activity in vitro 
to demonstrate greater absolute increases than mutant forms 
with low or zero baseline activity.
Assessment of the clinical validation of the GLP HEK assay
Mutant α-Gal A responses to migalastat in the GLP HEK assay 
and in male Fabry patient–derived lymphoblast cell lines in 
vitro were compared.
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Mutant α-Gal A responses to migalastat in the GLP HEK 
assay were compared with the pharmacodynamic effects of 
orally administered migalastat on:
•	 α-Gal A levels in PBMCs isolated from male Fabry 
patients.
•	 Mean number of globotriaosylceramide (GL-3) inclu-
sions per kidney interstitial capillary in male Fabry 
patients.
•	 Plasma globotriaosylsphingosine (lyso-Gb3) in male and 
female Fabry patients.
GLP HEK testing and amenability categorization of all 73 
unique mutations from phase II22,23 and phase III clinical stud-
ies (unpublished data; ref. 24) and 455 other Fabry disease–
associated mutations were completed prior to the availability of 
pharmacodynamic results from phase III studies.
The α-Gal A levels in PBMCs and lymphoblast cell lines were 
measured as previously described.11,16,22,23 The mean number 
of kidney GL-3 inclusions per interstitial capillary was deter-
mined.25 Plasma lyso-Gb3 was quantitatively analyzed by liq-
uid chromatography–mass spectroscopy using a novel, stable 
isotope-labeled internal standard13 called C6-lyso-Gb3 (unpub-
lished data).
The clinical studies included in these analyses are summa-
rized in Table 1. Supplementary Table S2 online lists the clini-
cal studies and other sources used for comparison with each 
pharmacodynamic endpoint (α-Gal A, kidney GL-3 inclusions, 
and plasma lyso-Gb3).
Comparison of amenable mutations from migalastat phase 
II and phase III clinical studies and all identified Fabry 
disease–associated amenable mutations
The following parameters were used to compare the two groups 
of amenable mutations:
1. Mean absolute increase and α-Gal A activity fold over 
baseline in response to 10 μmol/l migalastat
2. The proportion of amenable mutations grouped by 
phenotype
3. Mean baseline α-Gal A activity
4. Absolute increase and α-Gal A activity fold over baseline 
as a function of baseline
5. The proportion of conservative and nonconservative 
amino acid substitutions
6. The locations of the mutations within the structure of the 
GLA gene
7. The locations of substituted amino acid residues within 
the structure of α-Gal A
Pharmacogenetic reference table
Supplementary Table S11A,B online  categorizes GLA muta-
tions tested to date as amenable or nonamenable based on the 
GLP HEK assay.
RESULTS
Mutant α-Gal A responses in the GLP HEK assay
The 600 α-Gal A mutant forms that were tested spanned the 
length of the GLA gene and showed a wide range of enzyme 
activities at baseline and following incubation with 10 µmol/l 
migalastat (Supplementary Figure S2 online; Supplementary 
Table S1 online). In response to 10 μmol/l migalastat, 360 
mutant forms showed a statistically significant increase in α-
Gal A activity; 268 mutant forms—approximately 45%—met 
the amenable mutation criteria and 332 mutant forms did not.
Degree of consistency between mutant α-Gal A responses 
to migalastat in the GLP HEK assay and in male Fabry 
patient–derived lymphoblast cell lines
The α-Gal A activity in the absence and presence of a migala-
stat concentration-response curve (with top concentrations 
up to 20 mmol/l migalastat) were previously reported in 
74 male Fabry disease lymphoblast cell lines.11 Baseline activ-
ity and maximum α-Gal A activity after migalastat incuba-
tion in the GLP HEK assay (i.e., after 10 µmol/l migalastat) 
Table 1 Summary of clinical studies
Study number
Clinicaltrial.gov 
NCT number
Doses(s)/regimen(s) of 
migalastat HCl Inclusion criteria Design (number randomized)
FAB-CL-201 (study 201) 00214500 25, 100, 250 mg b.i.d.;  
50, 150 mg  q.o.d.
Males only; ERT-naive 12–24 months OL (n = 24)a
FAB-CL-202b (study 202) 00283959 150 mg q.o.d.
FAB-CL-203b (study 203) 00283933 150 mg q.o.d.
FAB-CL-204b (study 204) 00304512 50, 150,  250 mg q.o.d. Females only; ERT-naive 12–24 months OL (n = 9)
AT1001-011 (study 011) 00925301 150 mg q.o.d. Males and females; ERT-naive or not 
taken ≥6 months
6 months R, DB, PC;  
24 months OL (n = 67)
AT1001-012 (study 012) 01218659 150 mg q.o.d. Males and females with prior ERT 
≥12 months
18 months R, OL migalastat versus 
ERT; 12 months OL migalastat (n = 60)
b.i.d., twice per day; DB, double-blind; ERT, enzyme replacement therapy; OL, open-label; PC, placebo-controlled; q.o.d., every other day; R, randomized
aSix of the 24 patients only received 150 mg migalastat q.o.d. for 14 days as part of an in vivo screen. bPrimary research articles published.22,23 Institutional review board 
approval was obtained for all centers involved in the clinical studies. All patients gave written informed consent to participate.
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and the male lymphoblasts (i.e., at the top of the concentra-
tion-response curve) were significantly correlated (Pearson 
correlation coefficients (r) were 0.7375 (n = 74) and 0.7869 
(n = 74), respectively, with two-tailed P values <0.0001 for 
each). Although the correlations indicate a high degree of 
consistency in α-Gal A activity between the two assays, some 
mutant forms with high EC50 (effective concentration 50, i.e., 
the concentration of migalastat yielding 50% of the maximal 
effect) values and/or small statistically significant responses 
to migalastat in lymphoblasts did not meet the threshold 
level of response required by the amenable mutation criteria 
in GLP HEK assay. Thus, further comparison was evaluated 
by calculating the sensitivity and specificity after the ame-
nable mutation criteria were applied to both datasets. The 
sensitivity and specificity26,27 were calculated to be 0.92 and 
0.89, respectively (Supplementary Material online), again 
indicating a high degree of consistency between the two sets 
of results.
Comparison of mutant α-Gal A responses to migalastat in 
the GLP HEK assay and PBMCs in 51 male Fabry patients 
from phase II and phase III clinical studies
Supplementary Table S2 online provides the clinical study 
sources for these analyses. PBMCs derived from female 
patients were not included because the cells are a mixture 
that may express either wild-type or mutant α-Gal A.18 
Based on sensitivity, specificity, positive predictive  values, 
and negative predictive values (≥0.875, n = 51, Table 2; 
Supplementary Tables S3–S6 online), there was a high 
degree of consistency between the GLP HEK assay and male 
patient PBMC results from phase II and phase III clinical 
studies. The predictive values based on male patients in 
only phase II studies (all doses and regimens or only 150 mg 
every other day (q.o.d.) and phase III studies AT1001-011 
(study 011) or AT1001-012 (study 012) were also found to 
show high degrees of consistency. The ranges for all com-
parisons were as follows: sensitivity, 0.9375–1.0; specificity, 
0.75–1.0; positive predictive value, 0.875–1.0; and negative 
predictive value, 0.875–1.0 (Table 2; Supplementary Tables 
S3–S6 online).
Comparison of mutant α-Gal A responses to migalastat in 
the GLP HEK assay and Fabry patient substrate responses
Kidney interstitial capillary GL-3. In study 011 (ERT-naive 
patients), the absolute change in the mean number of GL-3 
inclusions per kidney interstitial capillary after 6 months of 
treatment with migalastat was calculated for evaluable male and 
female patients with amenable (n = 42) and nonamenable (n = 14) 
mutations and plotted as a function of the mean number of GL-3 
inclusions per kidney interstitial capillary at baseline (Figure 1a).
The results indicate that decreases in the mean number of 
GL-3 inclusions per kidney interstitial capillary were observed 
in patients with amenable mutations. Larger decreases in the 
mean number of GL-3 inclusions per kidney interstitial cap-
illary were observed with increasingly higher baseline values. 
In patients with nonamenable mutations, there were no consis-
tent reductions in GL-3 substrate.
The predictive values for mutant α-Gal A responses in the 
GLP HEK assay with respect to changes in the mean number 
of GL-3 inclusions per interstitial capillary in response to mig-
alastat were based on 18 male patients (n = 12 and n = 6 with 
amenable and nonamenable mutations, respectively) in study 
011 with a baseline kidney interstitial capillary GL-3 level ≥0.1. 
A positive response was defined as a decrease in kidney inter-
stitial capillary GL-3 after 6 months of migalastat treatment (an 
absolute change <0.0 from baseline). Three male patients were 
excluded from these analyses because their baseline interstitial 
capillary GL-3 was close to zero (<0.1 inclusions per capillary). 
All female patients were excluded because kidney interstitial 
capillary GL-3 levels were close to zero or more variable relative 
to male patients with levels ≥0.1, possibly due to the expression 
of a mixture of wild-type and mutant α-Gal A.18 There was a 
high degree of consistency between the GLP HEK assay results 
and kidney GL-3 findings, with all predictive values calculated 
to be 1.0 (Table 3; Supplementary Tables S7 and S8 online; see 
also Supplementary Material online).
Plasma Lyso-Gb3
In study 011 (ERT-naive patients), the absolute change in plasma 
lyso-Gb3 after 6 months of migalastat treatment was calculated for 
male and female patients with plasma lyso-Gb3 results (n = 44). 
Table 2 Assessment of consistency between α-Gal A responses from male-derived peripheral blood mononuclear cells in 
phase II and III studies and GLP HEK assay
Sensitivity Specificity
Positive 
predictive value
Negative 
predictive value
No. of different 
evaluable male patients
Phase II (all doses) 0.9375 1.0 1.0 0.875 23
Phase II (150 mg q.o.d.)a 1.0 1.0 1.0 1.0 14
AT1001-011 (150 mg q.o.d.) 1.0 0.75 0.875 1.0 22
AT1001-012 (150 mg q.o.d.) 1.0 1.0 1.0 1.0 15
All male patients (150 mg q.o.d.) 1.0 0.875 0.946 1.0 51
a150 mg migalastat HCl q.o.d.. Criteria for a positive peripheral blood mononuclear cell α-Gal A response: ≥2% of normal maximal net increase after oral administration of 
migalastat.
q.o.d., every other day.
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The results were grouped by the GLA mutation category 
for patients with amenable (n = 31) and nonamenable (n = 
13) mutations and plotted as a function of the baseline level 
(Figure 1b).
The results showed decreases within 6 months of treatment 
in plasma lyso-Gb3 in patients with amenable mutations, with 
larger decreases observed with increasingly higher baseline 
values. In patients with nonamenable mutations, there were no 
consistent reductions in lyso-Gb3.
The predictive values for mutant α-Gal A responses in the 
GLP HEK assay with respect to changes in plasma lyso-Gb3 
were based on 16 evaluable male patients (n = 11 and n = 
5 with amenable and nonamenable mutations, respectively) 
in study 011. A positive response was defined as a decrease 
in plasma lyso-Gb3 after 6 months of migalastat treatment 
(an absolute change <0.0 from baseline). There was a high 
degree of consistency between the GLP HEK assay results 
and plasma lyso-Gb3 findings (Table 3; Supplementary 
Table S8 online). All predictive values for male patients 
were calculated to be 1.0 (see also Supplementary Material 
online). The predictive values for all male and female 
patients (n  =  44; 31 amenable and 13 nonamenable muta-
tions) also indicated a high degree of consistency (Table 3; 
Supplementary Table S8 online).
In study 012, patients using ERT (agalsidase alfa or beta) 
either were randomized to continue receiving ERT or were 
switched to migalastat (150 mg q.o.d.) for 18 months. Of the 
60 patients randomized, 56 had amenable mutations and 4 
had nonamenable mutations. The results (Figure 2) showed 
that in patients with amenable mutations, the plasma lyso-
Gb3 levels remained stable for 18 months following a switch 
from ERT to migalastat, which is comparable to those seen 
in patients who continued using ERT. In patients with non-
amenable mutations (two males), plasma lyso-Gb3 levels 
increased following the switch from ERT to migalastat, as 
compared to two patients (one male and one female) who 
continued using ERT.
Exploratory comparison of the increase in α-Gal A activity 
for amenable mutant forms in the GLP HEK assay and 
substrate reduction in patients following migalastat 
treatment
The relationship between the quantitative GLP HEK assay 
responses for amenable mutant forms and the amount of sub-
strate reduction in patients with amenable mutations in study 
011 was explored. In the subset of amenable α-Gal A mutant 
forms, the GLP HEK assay absolute increase and α-Gal A activ-
ity fold over baseline were each compared with the absolute 
change in substrate after 6 months of treatment with migalastat 
in patients with amenable mutations in study 011:
•	 Absolute change in kidney GL-3 inclusions in male 
patients: Pearson correlation coefficients (r): 0.2172 (n = 
12; P = 0.4978) and −0.0712 (n = 11; P = 0.8353), respec-
tively (two-tailed P values) (Supplementary Figure S3 
online)
Figure 1 Substrate changes following migalastat treatment by 
amenability category. (a) (top): Kidney interstitial capillary GL-3 absolute 
change after 6 months of treatment with migalastat grouped by amenability 
category. Study 011 combines male and female patients receiving 6 months 
of migalastat (baseline to month 6 for patients randomized to migalastat 
at baseline, plus month 6 to month 12 for male patients receiving placebo 
from baseline to month 6). IC GL-3: mean number of GL-3 inclusions per 
interstitial capillary. Baseline refers to the kidney IC GL-3 value during the 
study 011 baseline visit (visit 1) for patients treated with migalastat during 
stages 1 and 2; it refers to the kidney IC GL-3 value at month 6 for patients 
treated with placebo during stage 1 and migalastat during stage 2. The mean 
(minimum, maximum) baseline IC GL-3 values for patients with amenable 
and nonamenable mutations were 0.646 (0.013, 5.692; n = 42) and 1.350 
(0.117, 5.248; n = 14), respectively. After 6 months of treatment, the mean 
changes (95% confidence interval) from baseline for patients with amenable 
and nonamenable mutations were −0.282 (−0.455, −0.109; n = 42) and 
0.324 (−0.105, 0.752; n = 14), respectively. The mean difference (95% 
confidence interval) in the change from baseline after 6 months (amenable 
minus nonamenable) was −0.606 (−1.059, −0.153). (b) (bottom): Plasma lyso-
Gb3 absolute change after 6 months of treatment with migalastat grouped 
by amenability category. Study 011 combines male and female patients 
receiving 6 months of migalastat (baseline to month 6 for patients randomized 
to migalastat at baseline, plus month 6 to month 12 for patients receiving 
placebo from baseline to month 6). Baseline refers to the plasma lyso-Gb3 value 
during the study 011 baseline visit (visit 1) for patients treated with migalastat 
during stage 1 and stage 2; it refers to the kidney IC GL-3 value at month 6 in 
patients treated with placebo during stage 1 and migalastat during stage 2. 
The mean (minimum, maximum) baseline plasma lyso-Gb3 values for patients 
with amenable and nonamenable mutations were 45.236 (1.187, 218.333; 
n = 31) and 74.396 (9.720, 249.333; n = 13), respectively. After 6 months 
of treatment, the mean changes (95% confidence interval) from baseline for 
patients with amenable and nonamenable mutations were −13.011 (−20.642, 
−5.380; n = 31) and 9.801 (−1.6478, 21.2498; n = 13), respectively. The 
mean difference (95% confidence interval) in the change from baseline after 
6 months (amenable minus nonamenable) was −22.812 (−36.100, −9.524).
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•	 Absolute change in plasma lyso-Gb3 in male patients: 
Pearson correlation coefficients (r): 0.1653 (n = 11; 
P = 0.6272) and −0.0248 (n = 10; P = 0.9458), respec-
tively (two-tailed P values) (Supplementary Figure S4 
online)
•	 Absolute change in plasma lyso-Gb3 in male and female 
patients: Pearson correlation coefficients (r): 0.0328 (n = 
31; P = 0.8608) and 0.2130 (n = 30; P = 0.2584), respec-
tively (two-tailed P values) (Supplementary Figure S5 
online)
Comparison of amenable mutations from migalastat phase 
II and phase III clinical studies and all identified Fabry 
disease–associated amenable mutations
Supplementary Tables S9 and S10 online list the unique ame-
nable (total = 51) and the unique nonamenable (total = 22) 
mutations from 160 patients in phase II and phase III clinical 
studies. Fifty-one different amenable mutations were identi-
fied in 126 patients, representing 19% (51/268) of all amenable 
mutations categorized to date. These 51 mutant forms of α-Gal 
A were compared to all 268 amenable mutations.
Mean absolute and fold over baseline response to  
10 μmol/l migalastat
The mean absolute increase and fold over baseline of the 
51 mutant forms (24.7 ± 1.7 and 6.1 ± 0.8, respectively) 
were comparable to the corresponding changes for all 268 
amenable mutations (23.7 ± 0.9 and 4.9 ± 0.3, respectively) 
(Supplementary Figure S6 online).
Proportion of amenable mutations grouped by phenotype
Clinical phenotypes based on published reports of Fabry dis-
ease–associated mutations tested in the GLP HEK assay are 
provided in the Supplementary Material online.
Based on published reports of clinical phenotypes associ-
ated with the amenable mutations of patients in clinical stud-
ies compared to all amenable mutations identified in the GLP 
HEK assay, the proportions of amenable mutations within each 
category were similar (Supplementary Figure S7 online). The 
majority were associated with the classic Fabry phenotype.
Additional comparisons
Results from additional comparisons of the two subsets of 
amenable mutations (Supplementary Figures S8–S12 online) 
Table 3 Assessment of consistency between mutant α-Gal A responses to migalastat in the GLP HEK assay and Fabry 
disease patient substrate responses in study 011
Parameter compared with GLP HEK assay Sensitivity Specificity
Positive  
predictive value
Negative  
predictive value No. of patients
Male kidney interstitial capillary GL-3 1.0 1.0 1.0 1.0 18
Male lyso-Gb3 1.0 1.0 1.0 1.0 16
Male and female lyso-Gb3 0.9286 0.6875 0.8387 0.8462 44
Patients with a kidney interstitial capillary GL-3 or plasma lyso-Gb3 absolute change <0.0 after 6 months of treatment with 150 mg migalastat HCl were categorized 
as having a positive response. Absolute change from baseline in Fabry substrate (i.e., kidney interstitial capillary GL-3 or plasma lyso-Gb3) is calculated as the value after 
6 months of migalastat treatment minus the value obtained immediately prior to treatment. The comparison to male kidney interstitial capillary GL-3 included only males 
with a baseline kidney interstitial capillary GL-3 level ≥0.1.
Figure 2 Plasma lyso-Gb3 absolute change from baseline after treatment with migalastat grouped by GLA mutation category. Study 012 changes 
from baseline in patients with amenable and nonamenable GLA mutations. Blue dotted lines represent zero change from baseline. Left: Data points represent 
the mean, error bars represent the standard deviation, and values in parentheses represent the number (n) of patients with amenable mutations. At month 
18, in patients with amenable mutations, the mean changes (95% confidence interval) from baseline for migalastat and ERT were 1.728 (−0.301, 3.758) 
and −1.926 (−4.632, 0.781), respectively. Right: Data points are from individual patients with nonamenable mutations. Lines represent the mean, values in 
parentheses represent the number (n) of patients with nonamenable mutations. Due to small sample sizes, no statistical comparisons were made for patients 
with nonamenable mutations. Data are based on patients with available samples for this analysis.
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indicate that the subset identified in the clinical studies is rep-
resentative of all amenable mutant forms identified by the 
GLP HEK assay. The amenable mutant forms with higher 
baseline activity tended to have a greater absolute increase 
(Supplementary Figure S9 online), whereas the α-Gal A activ-
ity fold over baseline was greater for those mutants with lower 
baseline activity (Supplementary Figure S10 online).
Pharmacogenetic reference table
A pharmacogenetic reference table that categorizes GLA 
mutations based on the GLP HEK assay was compiled 
(Supplementary Table S11A,B online). Two hundred 
sixty-eight GLA mutations met the amenable mutation cri-
teria (Supplementary Table S11A online) but 332 did not 
(Supplementary Table S11B online). The remaining 241 
mutations that included large deletions, insertions, truncations, 
frameshift mutations, and splice-site mutations did not qualify 
for testing in the GLP HEK assay and were categorized as nona-
menable without testing.
DISCUSSION
The GLP-validated HEK assay (migalastat amenability assay) 
was developed to identify Fabry patients with amenable mutant 
forms of α-Gal A for treatment with migalastat. The assay does 
not require patient samples and is applicable to male and female 
patients. Approximately 800 GLA Fabry disease–causing muta-
tions have been identified to date, with the majority being mis-
sense. Previous reports had speculated that an in vitro assay that 
measures the mutant α-Gal A response to migalastat may be 
useful in the identification of Fabry patients for treatment with 
a pharmacological chaperone.16,17 The results obtained with the 
GLP HEK assay provide clinical validation and generalizability 
of the assay for identification of male and female patients with 
Fabry disease for treatment with migalastat.
The predictive value of the GLP HEK assay and the ame-
nability criteria were assessed based on Fabry patient phar-
macodynamic responses in phase II and III clinical studies. 
Seventy-three unique amenable and nonamenable muta-
tions were represented in these studies. The mutant α-Gal 
A responses in the GLP HEK assay were compared to α-Gal 
A activity and levels of disease substrate (kidney GL-3 and 
plasma lyso-Gb3). The accumulation of GL-3 in different kid-
ney cell types is a known consequence of Fabry disease,1 and 
reduction of this substrate is a recognized beneficial treatment 
outcome.22,28 Plasma lyso-Gb3 also has become increasingly rec-
ognized as an important marker of disease severity.29,30
The comparisons between the GLP HEK assay amenable/
nonamenable mutation results, PBMC α-Gal A activity, and 
disease substrate responses for Fabry patients after oral admin-
istration of migalastat revealed a high degree of consistency. 
High sensitivity, specificity, positive predictive values, and 
negative predictive values strongly support the clinical valid-
ity of the GLP HEK assay for identifying Fabry disease patients 
amenable to treatment with migalastat. The analysis of the GLP 
HEK assay responses for amenable mutant forms indicated that 
these cell-based results did not quantitatively predict the mag-
nitude of substrate reduction in treated patients. This is perhaps 
not surprising because, as with other treatments for Fabry, the 
magnitude of substrate reduction may be affected by many fac-
tors, including baseline disease severity, systemic risk factors, or 
modifier genes.31,32
The characteristics of the amenable mutant forms of α-Gal 
A from patients were similar to those for all amenable mutant 
forms categorized to date with the GLP HEK assay. Comparisons 
included absolute increases in α-Gal A activity, α-Gal A activ-
ity fold over baseline, the proportions associated with differ-
ent Fabry phenotypes, and locations of the substituted amino 
acids. A majority (~70%) of amenable mutations in the clinical 
study subset and the larger subset were associated with clas-
sic Fabry disease based on published literature describing these 
mutations. The classic Fabry phenotype describes patients with 
early-onset, low residual α-Gal A activity (in male patients), 
multi-organ system disease, and elevated plasma lyso-Gb3.29,33,34 
This indicates that patients amenable to treatment with migala-
stat commonly have classic Fabry disease.
The pharmacogenetic reference table (Supplementary Table 
S11A,B online) categorizes the amenability of approximately 
800 Fabry disease–associated mutations. Six hundred quali-
fied mutant forms of α-Gal A were tested with the GLP HEK 
assay. Two hundred sixty-eight met the amenability criteria. 
The majority of amenable mutations were missense, but some 
were small in-frame insertions or deletions. GLA mutations 
that did not qualify for testing with the GLP HEK assay were 
most commonly large deletions, insertions, truncations, frame-
shift mutations, and splice-site mutations, which often led to 
the loss of gross structural protein domains and loss of α-Gal A 
expression. These were considered nonamenable without test-
ing with the GLP HEK assay. The pharmacogenetic reference 
table can be integrated into clinical practice to identify patients 
for treatment with migalastat and updated as new mutations 
are identified. The standard diagnostic workup for patients with 
Fabry disease includes genotyping to confirm the presence of a 
GLA mutation.
Because we primarily used Human Gene Mutation Database 
and literature-based sources to identify Fabry disease–associ-
ated mutations, the classifications of pathogenicity may vary or 
may be debatable for some. Most α-Gal A mutant forms studied 
with the GLP HEK assay have little to no baseline activity, sug-
gesting pathogenicity. However, some mutant forms have been 
identified with normal or near-normal baseline activity in the 
GLP HEK assay. The GLP HEK assay and the pharmacogenetic 
reference table are not intended to be used to define mutations 
as pathogenic or to aid in the diagnosis of Fabry disease. The 
intended use is to identify Fabry patients with amenable mutant 
forms of α-Gal A for treatment with migalastat.
Orally administered migalastat is being developed as an alter-
native to ERT for the treatment of Fabry disease in patients with 
amenable mutations. Migalastat acts as a pharmacologic chap-
erone by selectively and reversibly binding to the active site of 
amenable mutant forms of α-Gal A. Migalastat binding to and 
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stabilizing amenable mutant forms of α-Gal A may increase 
α-Gal A enzyme levels in a more consistent fashion than ERT 
infusions every other week. The higher volume of distribution 
of migalastat relative to ERT19 suggests that the pharmacologi-
cal chaperone is distributed to many different cells and tissues, 
which may enhance α-Gal A levels in multiple organs, includ-
ing the brain.8 As an orally administered small molecule, ERT-
associated immunogenicity and infusion-associated reactions 
would be avoided with migalastat.
In recently completed phase III studies (unpublished data; ref. 
24), migalastat treatment resulted in significant reductions in dis-
ease substrate in patients with amenable mutations, with efficacy 
in organ systems affected by the disease. The development and 
clinical validation of the GLP-validated HEK assay were critical 
for identifying Fabry patients with mutant forms of α-Gal A that 
are amenable to treatment with migalastat. Based on the current 
study, the GLP HEK assay is now a clinically validated pharma-
cogenetic method of identifying male and female Fabry patients 
for treatment with migalastat. The associated pharmacogenetic 
reference table could be integrated into clinical practice.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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